Creative Medical Technology Holdings (CELZ) Amortization - Intangibles (2016 - 2026)
Creative Medical Technology Holdings' (CELZ) quarterly Amortization - Intangibles came in at $22918.0 in Q2 2026, down 25.45% year-over-year from $30742.0 in Q2 2025, and down 20.58% quarter-over-quarter from $28855.0 in Q1 2026.
Analysis
Creative Medical Technology Holdings (CELZ) Amortization - Intangibles (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Amortization - Intangibles for 11 consecutive years, with $22918.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Amortization - Intangibles fell 25.45% year-over-year to $22918.0 in Q2 2026; TTM through Jun 2026 was $113781.0, a 0.49% change from a year earlier, with the FY2025 full-year figure at $123327.0, up 11.66% from the prior year.
- Amortization - Intangibles was $22918.0 for Q2 2026 at Creative Medical Technology Holdings, down from $28855.0 in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $31059.0 in Q3 2025 and troughed at $22639.0 in Q4 2024.
- A 5-year average of $26234.4 and a median of $24271.0 in 2022 frame the typical range for Amortization - Intangibles.
- Across the five-year window, Amortization - Intangibles soared 36.71% in 2025 and retreated 25.45% in 2026, its largest moves.
- Over 5 years, Amortization - Intangibles stood at $23021.0 in 2022, then grew by 10.86% to $25521.0 in 2023, then fell by 11.29% to $22639.0 in 2024, then jumped by 36.71% to $30949.0 in 2025, then retreated by 25.95% to $22918.0 in 2026.
- The last three Amortization - Intangibles figures came in at $22918.0 (Q2 2026), $28855.0 (Q1 2026), and $30949.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Creative Medical Technology Holdings | 1.45 Mn | 1.45 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22,918.00 |
| Mar 31, 2026 | 28,855.00 |
| Dec 31, 2025 | 30,949.00 |
| Sep 30, 2025 | 31,059.00 |
| Jun 30, 2025 | 30,742.00 |
| Mar 31, 2025 | 30,577.00 |
| Dec 31, 2024 | 22,639.00 |
| Sep 30, 2024 | 29,271.00 |
| Jun 30, 2024 | 29,271.00 |
| Mar 31, 2024 | 29,271.00 |
| Dec 31, 2023 | 25,521.00 |
| Sep 30, 2023 | 23,021.00 |
| Jun 30, 2023 | 23,021.00 |
| Mar 31, 2023 | 23,021.00 |
| Dec 31, 2022 | 23,021.00 |
| Sep 30, 2022 | 23,021.00 |
| Jun 30, 2022 | 23,021.00 |
| Mar 31, 2022 | 23,021.00 |
| Dec 31, 2021 | 23,021.00 |
| Sep 30, 2021 | 23,021.00 |